Tandem Diabetes Care reports developments in automated insulin delivery and diabetes technology. The company manufactures and sells pump systems including Tandem Mobi and the t:slim X2 insulin pump, both powered by Control-IQ+ advanced hybrid closed-loop technology. News commonly covers FDA clearances, pump and mobile-app compatibility, continuous glucose monitoring integrations, and product portfolio updates for people with diabetes.
Company updates also address quarterly and annual operating results, worldwide and U.S. sales trends, pump shipments, gross margin, financial guidance, reimbursement-model changes, investor conference presentations, and capital actions such as convertible debt financing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Tandem Diabetes Care (NASDAQ: TNDM) announced a company update presentation scheduled for May 10, 2023, at 4:40 PM Eastern Time during the BofA Securities 2023 Health Care Conference. The live event will be accessible via webcast, with an archive available for 30 days afterward.
The presentation will highlight Tandem's commitment to innovation in insulin delivery and diabetes technology, emphasizing their human-centered design approach. The company manufactures the t:slim X2 insulin pump featuring Control-IQ technology, aimed at enhancing the management of diabetes for users and healthcare providers.
For more details, the webcast link can be found on Tandem’s Investor Center website under the “Events & Presentations” section.
Tandem Diabetes Care (NASDAQ: TNDM) announced a publication in Diabetes Technology & Therapeutics of a meta-analysis from three randomized controlled trials showcasing its Control-IQ advanced hybrid closed-loop technology. The study highlights significant improvements in glucose control, with an average increase in time in range of 2.8 hours and a reduction in hemoglobin A1c levels across diverse demographics, including ages 2 to 72. Those with the highest baseline blood sugar benefited most from the automatic correction bolusing feature. The results indicate broad applicability of Control-IQ technology, enhancing diabetes management effectiveness. Notably, the technology's comprehensive data set supports its advantages over competing automated insulin delivery systems.
Tandem Diabetes Care plans to release its first quarter 2023 results on May 3, 2023, after market close. A conference call will take place at 4:30 PM ET to discuss financial and operating results. Investors can access the live webcast on the company's Investor Center website. The event will provide insights into the company's performance, focusing on innovative diabetes technology products such as the t:slim X2 insulin pump with Control-IQ technology. Tandem Diabetes Care aims to enhance the experience for individuals managing diabetes through its human-centered approach.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced favorable results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial, published in the New England Journal of Medicine. Children aged 2-5 using the t:slim X2 insulin pump with Control-IQ technology experienced an approximate 3-hour daily increase in time in range compared to standard insulin treatments. Key findings showed a 12.4% adjusted mean difference in time in range and a 0.5% decrease in Hemoglobin A1c levels. The trial included 101 participants, with 94% system usability, indicating significant improvements in glucose control.